Mechanisms of endosomal dysfunction at synapses in a-synuclein pathology

Active Grant Awarded

Award ID
R00NS126575
Recipient
Awarding agency
Obligated
$193,055

Award facts

Completion date 7% complete
Place of performance
Savannah, GA 31419, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Neurological Disorders and Stroke, part of the Department of Health and Human Services, awarded Georgia Southern University Research & Service Foundation Inc. a grant of $193,055 on September 9, 2026, under Assistance Listing 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders. The award, Grant R00NS126575, funds research on how distinct alpha-synuclein species disrupt endosomal trafficking at synapses, using the lamprey synapse model to deliver purified alpha-synuclein directly into synapses and measure effects on presynaptic ultrastructure and function. Aim 1 (K99) determines how monomeric human alpha-synuclein affects synaptic endosomal trafficking. Aim 2 (R00) examines how oligomeric species, including dimers, small oligomers, and larger oligomers isolated from PD/DLB human brains, contribute to alpha-synuclein-mediated endosomal dysfunction. The period of performance runs to June 30, 2029. Place of performance is Savannah, Georgia 31419. The award is a grant, and the source names no sub-recipients.

Description

Abstract
/summary synucleinopathies, including parkinson's disease (PD) and dementia with lewy bodies (DLB), are neurodegenerative diseases characterized by the abnormal aggregation of Α-synuclein. Furthermore, IT is well known that Α-synuclein exists in multiple structural forms (i.e., monomers and oligomers) that contribute to neurotoxicity by distinct mechanisms. While there is substantial evidence that accumulation of Α-synuclein broadly impairs synaptic vesicle endocytosis, the effects of distinct Α-synuclein species on synaptic endosomal trafficking are largely unknown. The proposed studies will be the first to investigate in detail how accumulation of different oligomeric Α-synuclein species affect endosomal trafficking at vertebrate synapses and the underlying cellular and molecular mechanisms. Using the lamprey synapse model, a classical vertebrate model, we can deliver precise amounts of purified -synuclein species directly into synapses. This allows US to independently test the effects of different -synuclein species on presynaptic ultrastructure and function. Our preliminary studies suggest that excess monomeric -synuclein impairs endosomal trafficking, as shown by a reduction in the number of synaptic vesicles and concomitant increase in the number of atypical large vesicles, reminiscent of endosomes. This provides an excellent model for the proposed studies. In aim 1 (K99), we will determine how monomeric human -synuclein affects endosomal trafficking at synapses. In aim 2 (R00), we will determine how oligomeric human -synuclein contribute to -synuclein-mediated endosomal dysfunction at synapses. The focus will be on different oligomeric -synuclein species including dimers, small oligomers and larger oligomers from PD/DLB human brains. These studies will provide critical understanding for the development of therapies for improving synaptic function in synucleinopathies.

Quick answers

Who received award R00NS126575?

R00NS126575 was awarded to Georgia Southern University Research & Service Foundation Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 9, 2026.

How much is award R00NS126575 worth?

$193,055 has been obligated on R00NS126575.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award